Home' Australian Pharmacist : Australian Pharmacist December 2014 Contents Australian Pharmacist December 2014 I ©Pharmaceutical Society of Australia Ltd.
Ultibro Breezhaler 110/50
Approved by the Therapeutic Goods
Administration (TGA) in March,
Australia’s first once-daily dual
bronchodilator for maintenance
treatment of chronic obstructive
pulmonary disease (COPD) is now
listed on the Pharmaceutical Benefits
Scheme (PBS). According to Novartis,
Ultibro Breezhaler 110/50 (indacaterol/
glycopyrronium), which combines
the long-acting beta2-adrenergic
agonist (LABA) indacaterol maleate,
and long-acting muscarinic antagonist
(LAMA) glycopyrronium bromide,
is the first once-daily combination
bronchodilator reimbursed in Australia
to relieve symptoms in patients with
COPD who have been stabilised on a
LABA and LAMA bronchodilator.
Both the Australian and New Zealand
Guidelines for the management of COPD
(COPD-X) and international guidelines
developed by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
recommend bronchodilation with LABA
and / or LAMA for people with moderate
to severe COPD, along with smoking
cessation and regular exercise. Dual
bronchodilation with Ultibro Breezhaler
110/50 combines two approved and
already available Novartis COPD
treatments: LABA, indacaterol maleate,
and the LAMA, glycopyrronium bromide.
The Ultibro Breezhaler 110/50 is
delivered via the Breezhaler device
which allows patients to hear, feel
and see that they have taken the full
dose correctly. The Ultibro Breezhaler
110/50-clinical trial program IGNITE
consists of 11 studies and involved more
than 10,000 patients across 52 countries.
Soliris (eculizumab), a new treatment for
atypical Haemolytic Uraemic Syndrome
(aHUS) – an ultra-rare disease that
severely damages vital organs like the
heart, brain and kidneys was PBS listed
on 1 December. It affects both adults
and children and is often fatal. The PBS
listing of Eculizumab will help patients
affected by aHUS control the symptoms
and severity of attacks and can also help
restore organ function.
Before its listing on the PBS,
the average cost of the treatment was
$500,000 a year per patient, putting
it out of the reach of most Australian
families according to Health Minister
‘ The Government has been able to
fund this medicine because of the
incredible and tireless work of patients
and clinicians to develop the criteria
to manage its use in Australia,’ he
said. The Government has approved
$63 million over the next four years to
provide eculizumab on the PBS.
Nature’s Own has launched an
Omega-3 formulation combining
microalgae derived DHA, Aquamin
and concentrated fish oil. Eight times
stronger than Natures OwnKrill, the
patented Red Algal formulation high in
DHA, is sourced directly from the same
micro-algae that fish, krill and calamari
obtain their Omega-3, making it a
more potent source of the key nutrient,
according to the company.
Considered one of the most complex yet
powerful forms of Omega-3, DHA is an
essential fatty acid that may be difficult
to get from diet alone if you don’t eat
the recommended amount of oily fish
and has been shown to play a key role in
brain function and cognition.
While it is widely understood that
Omega-3 is the key to healthy ageing
with benefits spanning general health
as well as heart, brain memory, eye and
joint health, scientific evidence has
identified that it is the DHA level that
offers the greatest health benefits.
Nature’s Own Red Algal is available
in pharmacies and grocery stores.
Pharmacies will be supported with
a range of point of sale material,
naturopathic training, as well as a Nosy
Club module for pharmacy assistants.
Also available will be a Red Algal + Krill
1. Tkacz VL, Metzger A, Pruchnicki MC. Health literacy in
pharmacy. American Journal of Health-System Pharmacy.
2. Hamrosi KK, Raynor DK, Aslani P. Enhancing provision of
written medicine information in Australia: pharmacist,
general practitioner and consumer perceptions of the
barriers and facilitators. BMC Health Services Research.
3. Koo M, Krass I, Aslani P. Enhancing patient education
about medicines: factors influencing reading and seeking
of written medicine information. Health Expectations.
4. Usher W T. Australian Health Professionals’ Health Website
Recommendation Trends. Health Promotion Journal
of Australia: Official Journal of Australian Association of
Health Promotion Professionals. 2011;22(2):134.
5. Johnson JL, Moser L, Garwood CL. Health literacy: A primer
for pharmacists. American Journal of Health-System
Pharmacy. 2013;70(11):949–55 .
6. Emmerton LM, Mampallil L, Kairuz T, McKauge LM, Bush
RA. Exploring health literacy competencies in community
pharmacy. Health Expectations. 2012;15(1):12–22 .
References from Be our guest page 18.
Links Archive Australian Pharmacist November 2014 Australian Pharmacist January 2015 Navigation Previous Page Next Page